Skip to search formSkip to main contentSkip to account menu

MK 0646

Known as: MK-0646, MK0646 
National Institutes of Health

Related topics

Related topics

2 relations
Monoclonal Antibodies

Broader (1)

dalotuzumab

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Additional file 2: of Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma
The most commonly reported grade 3 and 4 toxicity in patients treated with gemcitabine + MK-0646 versus gemcitabine + erlotinib… 
2013
2013
Abstract 3887: The expression and clinical significance of Ezrin in colorectal cancer metastasis.
Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC Introduction: Colorectal Cancer(CRC) metastasis to… 
2011
2011
Cancer Therapy : Clinical A Phase I Pharmacokinetic and Pharmacodynamic Study of Dalotuzumab ( MK-0646 ) , an Anti-Insulin-like Growth Factor-1 Receptor Monoclonal Antibody , in Patients with…
Purpose: Insulin-like growth factor-1 receptor (IGF-1R) mediates cellular processes in cancer and has been proposed as a… 
2010
2010
Phase I/II study of MK-0646, the humanized monoclonal IGF-1R antibody in combination with gemcitabine or gemcitabine plus erlotinib (E) for advanced pancreatic cancer.
4039 Background: MK-0646 binds to IGF-1R and blocks its interaction with IGF-I/ II ligands, enhances gemcitabine (G)-induced… 
2010
2010
A phase II clinical trial of MK-0646, an insulin-like growth factor-1 receptor inhibitor (IGF-1R), in patients with metastatic well-differentiated neuroendocrine tumors (NETs).
4163 Background: Preclinical studies have implicated the IGF-1 receptor in the progression of neuroendocrine tumors. A therapy… 
2010
2010
Effect of EGFR and IGF1R on feedback activation of AKT arising from inhibition of mTOR in malignant pleural mesothelioma (MPM).
e13607 Background: NF2 inactivation is one of the major genetic alterations in MPM and has recently been causally associated with… 
2010
2010
Preclinical analysis of IGF-IR antibody MK-0646 in endometrial cancer
2008
2008
Gateways to clinical trials. July-August 2008.
(-)-Epigallocatechin gallate, 501516, 89-12; Abatacept, Adalimumab, Adefovir dipivoxil, AG-701, Agatolimod sodium, Alefacept… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)